Automate Your Wheel Strategy on DYN
With Tiblio's Option Bot, you can configure your own wheel strategy including DYN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DYN
- Rev/Share 0.0138
- Book/Share 5.0183
- PB 2.6782
- Debt/Equity 0.039
- CurrentRatio 16.8294
- ROIC -0.6367
- MktCap 1912028160.0
- FreeCF/Share -3.1784
- PFCF -5.2829
- PE -3.7067
- Debt/Assets 0.0305
- DivYield 0
- ROE -0.6412
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | DYN | Raymond James | Outperform | Strong Buy | -- | $35 | Aug. 25, 2025 |
| Initiation | DYN | Bernstein | -- | Market Perform | -- | $13 | June 24, 2025 |
| Resumed | DYN | Raymond James | -- | Outperform | -- | $37 | June 11, 2025 |
| Resumed | DYN | Oppenheimer | -- | Outperform | -- | $34 | June 2, 2025 |
| Initiation | DYN | Evercore ISI | -- | Outperform | -- | $46 | May 29, 2025 |
| Initiation | DYN | BMO Capital Markets | -- | Outperform | -- | $50 | March 12, 2025 |
| Initiation | DYN | Scotiabank | -- | Sector Outperform | -- | $50 | March 7, 2025 |
| Initiation | DYN | Robert W. Baird | -- | Outperform | -- | $46 | Dec. 13, 2024 |
News
Dyne Therapeutics, Inc. (DYN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Dyne Therapeutics, Inc. (NASDAQ:DYN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 9:15 AM EDT Company Participants John Cox - CEO, President & Director Erick Lucera - CFO, Principal Financial Officer & Principal Accounting Officer and Treasurer Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference.
Read More
Dyne Therapeutics to Present at Upcoming Investor Conferences
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to present at the following upcoming investor conferences:
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
Published: August 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. (“Dyne” or the “Company”) (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
Published: August 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. (“Dyne” or the “Company”) (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect?
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Dyne Therapeutics (DYN) points to a 285.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
Published: July 31, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
Published: July 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. (“Dyne” or the “Company”) (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
Published: July 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
Published: July 07, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
Published: July 02, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Published: July 01, 2025 by: Benzinga
Sentiment: Negative
U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Tuesday.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
Published: June 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Dyne Therapeutics, Inc. – DYN
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. (“Dyne” or the “Company”) (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Dyne Therapeutics - Emergence As A Superior DM1 / DMD Player Warrants Rating Upgrade
Published: June 18, 2025 by: Seeking Alpha
Sentiment: Positive
Upgrading Dyne Therapeutics to 'Buy' due to promising late-stage DM1 and DMD drug candidates and significant unmet need in both indications. Recent management changes and a more measured clinical approach improve confidence in Dyne's ability to deliver safe, effective therapies. Key data catalysts for DYNE-251 and DYNE-101 are expected in late 2025 and H1 2026, with potential accelerated approval submissions by late 2026.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
Published: June 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. (“Dyne” or the “Company”) (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
- DYNE-302 Demonstrated Functional Improvement in an FSHD Preclinical Model - WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that it will be presenting new preclinical data demonstrating the potential of DYNE-302 to achieve functional improvement in facioscapulohumeral muscular dystrophy (FSHD).
Read More
Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
- FDA (CDER) Type C meeting held in May 2025 for DYNE-101 in DM1 and Dyne plans to provide a regulatory update following receipt of meeting minutes -
Read More
Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker
Published: March 13, 2025 by: Seeking Alpha
Sentiment: Positive
Positive biomarker and functional data released from phase 1/2 ACHIEVE study, using DYNE-101 to treat patients with Myotonic Dystrophy Type 1. Data from registration cohort phase 1/2 ACHIEVE study, using DYNE-101 to treat patients with Myotonic Dystrophy Type 1, expected in the 1st half of 2026. With positive data released from phase 1/2 ACHIEVE study, plus FDA allowing splicing correction as a surrogate biomarker, it sets up a possible Accelerated Approval filing of DYNE-101 in 2026.
Read More
About Dyne Therapeutics, Inc. (DYN)
- IPO Date 2020-09-17
- Website https://www.dyne-tx.com
- Industry Biotechnology
- CEO John G. Cox
- Employees 192